Mountain Crest Acquisition Corp. II
Status: Deal Closed
U=S+R
R=S/10
| IPO Proceeds, $M | $57.50M |
|---|---|
| IPO Date | Jan 8, 2021 |
| CEO | Suying Liu |
| Left Lead | Chardan |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 9+6 |
| IPO Sector |
General
North America |
| IPO Geography | US/Canada |
| Target Company | Better Therapeutics |
| Deal Announced | Apr 7, 2021 |
| Deal Size, $M | $184.00M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Oct 27, 2021 |
| Amendment Vote | TBD |
| Closing Date | Oct 28, 2021 |
Formerly MCAD
BTTX
| Price | $0.00 |
|---|---|
| Last closing price | $0.00 |
| H/L, 52-week | $0.14 / $1.61 |
| Volume, today | 1,588 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Mountain Crest Acquisition Corp. II:
- Structure and cap table
- 5 directors & officers
- 23 filings and events
- 2 underwriters
- 4 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Suying Liu | 32 | Chairman and CEO |
| Dong Liu | 35 | CFO and Director |
| Nelson Haight | 55 | Director |
| Todd Milbourn | 51 | Director |
| Wenhau Zhang | 50 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Chardan | BR | 4,950,000 | units |
| B. Riley FBR | 50,000 | ||
| 5,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.00 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.